Inactief instrument
Koers Eiger BioPharmaceuticals
Aandelen
EIGR
US28249U2042
Biotechnologie & Medisch Onderzoek
Verhandeld op OTC Markets| Bedrijfsleider | Titel | Leeftijd | Van |
|---|---|---|---|
| Hoofd Techniek/Wetenschap/O&O | 59 | 18-04-2022 | |
Douglas Staut
PRN | Corporate Officer/Principal | - | 19-04-2024 |
| Datum | Insider | Type | Hoofdpost | Volume | % marktkap. | Belang |
|---|---|---|---|---|---|---|
| 31/10/23 | Propel Bio Management LLC
| Koop | Onderneming | 278.239 | 0,6281% | |
| 31/10/23 | Propel Bio Management LLC
| Koop | Onderneming | 24.332 | 0,0549% | |
| 18/10/23 | Propel Bio Management LLC
| Andere | Onderneming | 5.096.986 | 11,5065% |
Toevoegen aan een lijst 0 geselecteerde | Verschil (%) | Varia. 5d. | Varia. 1j. | Varia. 3j. | Kap.($) | |
|---|---|---|---|---|---|---|
| -.--% | +6,25% | - | - | 12,59 mln. | ||
| -1,29% | -3,91% | +51,98% | +69,06% | 65,56 mld. | ||
| -2,21% | -0,69% | +8,30% | +89,74% | 60,41 mld. | ||
| -0,60% | +0,85% | +23,58% | +87,77% | 55,76 mld. | ||
| -1,26% | -1,45% | +12,43% | +117,42% | 46,98 mld. | ||
| -0,15% | -5,06% | +20,00% | +29,27% | 43,63 mld. | ||
| -3,15% | -16,63% | +146,30% | +685,27% | 36,09 mld. | ||
| +0,23% | +2,14% | +14,85% | +46,22% | 36,7 mld. | ||
| -1,42% | -2,49% | +76,77% | +57,51% | 32,9 mld. | ||
| +1,42% | +5,84% | -36,40% | +402,78% | 26,96 mld. | ||
| Gemiddelde | -0,85% | -1,64% | +35,31% | +176,12% | 45 mld. | |
| Gewogen gemiddelde per kap. | -1,07% | -1,58% | +34,69% | +150,17% |
Werknemers
25
















